Yi Lu1, Arvid Sjölander2, Martin Cederlöf2, Brian M D'Onofrio3, Catarina Almqvist4, Henrik Larsson5, Paul Lichtenstein2. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden2Statistical Genetics, Genetics, and Computational Biology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden3Department of Psychological and Brain Sciences, Indiana University, Bloomington. 4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden4Pediatric Allergy and Pulmonology Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden5School of Medical Sciences, Örebro University, Örebro, Sweden.
Abstract
Importance: Individuals with attention-deficit/hyperactivity disorder (ADHD) are at greater risk for academic problems. Pharmacologic treatment is effective in reducing the core symptoms of ADHD, but it is unclear whether it helps to improve academic outcomes. Objective: To investigate the association between the use of ADHD medication and performance on higher education entrance tests in individuals with ADHD. Design, Setting, and Participants: This cohort study observed 61 640 individuals with a diagnosis of ADHD from January 1, 2006, to December 31, 2013. Records of their pharmacologic treatment were extracted from Swedish national registers along with data from the Swedish Scholastic Aptitude Test. Using a within-patient design, test scores when patients were taking medication for ADHD were compared with scores when they were not taking such medication. Data analysis was performed from November 24, 2015, to November 4, 2016. Exposures: Periods with and without ADHD medication use. Main Outcomes and Measures: Scores from the higher education entrance examination (score range, 1-200 points). Results: Among 930 individuals (493 males and 437 females; mean [SD] age, 22.2 [3.2] years) who had taken multiple entrance tests (n = 2524) and used ADHD medications intermittently, the test scores were a mean of 4.80 points higher (95% CI, 2.26-7.34; P < .001) during periods they were taking medication vs nonmedicated periods, after adjusting for age and practice effects. Similar associations between ADHD medication use and test scores were detected in sensitivity analyses. Conclusions and Relevance: Individuals with ADHD had higher scores on the higher education entrance tests during periods they were taking ADHD medication vs nonmedicated periods. These findings suggest that ADHD medications may help ameliorate educationally relevant outcomes in individuals with ADHD.
Importance: Individuals with attention-deficit/hyperactivity disorder (ADHD) are at greater risk for academic problems. Pharmacologic treatment is effective in reducing the core symptoms of ADHD, but it is unclear whether it helps to improve academic outcomes. Objective: To investigate the association between the use of ADHD medication and performance on higher education entrance tests in individuals with ADHD. Design, Setting, and Participants: This cohort study observed 61 640 individuals with a diagnosis of ADHD from January 1, 2006, to December 31, 2013. Records of their pharmacologic treatment were extracted from Swedish national registers along with data from the Swedish Scholastic Aptitude Test. Using a within-patient design, test scores when patients were taking medication for ADHD were compared with scores when they were not taking such medication. Data analysis was performed from November 24, 2015, to November 4, 2016. Exposures: Periods with and without ADHD medication use. Main Outcomes and Measures: Scores from the higher education entrance examination (score range, 1-200 points). Results: Among 930 individuals (493 males and 437 females; mean [SD] age, 22.2 [3.2] years) who had taken multiple entrance tests (n = 2524) and used ADHD medications intermittently, the test scores were a mean of 4.80 points higher (95% CI, 2.26-7.34; P < .001) during periods they were taking medication vs nonmedicated periods, after adjusting for age and practice effects. Similar associations between ADHD medication use and test scores were detected in sensitivity analyses. Conclusions and Relevance: Individuals with ADHD had higher scores on the higher education entrance tests during periods they were taking ADHD medication vs nonmedicated periods. These findings suggest that ADHD medications may help ameliorate educationally relevant outcomes in individuals with ADHD.
Authors: B M Psaty; T D Koepsell; D Lin; N S Weiss; D S Siscovick; F R Rosendaal; M Pahor; C D Furberg Journal: J Am Geriatr Soc Date: 1999-06 Impact factor: 5.562
Authors: John Fayyad; Nancy A Sampson; Irving Hwang; Tomasz Adamowski; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Laura H S G Andrade; Guilherme Borges; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Chiyi Hu; Elie G Karam; Sing Lee; Fernando Navarro-Mateu; Siobhan O'Neill; Beth-Ellen Pennell; Marina Piazza; José Posada-Villa; Margreet Ten Have; Yolanda Torres; Miguel Xavier; Alan M Zaslavsky; Ronald C Kessler Journal: Atten Defic Hyperact Disord Date: 2016-11-19
Authors: Stephen V Faraone; Philip Asherson; Tobias Banaschewski; Joseph Biederman; Jan K Buitelaar; Josep Antoni Ramos-Quiroga; Luis Augusto Rohde; Edmund J S Sonuga-Barke; Rosemary Tannock; Barbara Franke Journal: Nat Rev Dis Primers Date: 2015-08-06 Impact factor: 52.329
Authors: Greta M Massetti; Benjamin B Lahey; William E Pelham; Jan Loney; Ashley Ehrhardt; Steve S Lee; Heidi Kipp Journal: J Abnorm Child Psychol Date: 2007-10-17
Authors: Linda A Wietecha; David W Williams; Michael Herbert; Raun D Melmed; Michael Greenbaum; Kory Schuh Journal: J Child Adolesc Psychopharmacol Date: 2009-12 Impact factor: 2.576
Authors: J Graham; T Banaschewski; J Buitelaar; D Coghill; M Danckaerts; R W Dittmann; M Döpfner; R Hamilton; C Hollis; M Holtmann; M Hulpke-Wette; M Lecendreux; E Rosenthal; A Rothenberger; P Santosh; J Sergeant; E Simonoff; E Sonuga-Barke; I C K Wong; A Zuddas; H-C Steinhausen; E Taylor Journal: Eur Child Adolesc Psychiatry Date: 2010-11-03 Impact factor: 4.785
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Wilson M Compton; Beth Han; Carlos Blanco; Kimberly Johnson; Christopher M Jones Journal: Am J Psychiatry Date: 2018-04-16 Impact factor: 18.112
Authors: Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson Journal: Biol Psychiatry Date: 2019-04-17 Impact factor: 13.382
Authors: Ana Pérez-Vigil; Lorena Fernández de la Cruz; Gustaf Brander; Kayoko Isomura; Andreas Jangmo; Inna Feldman; Eva Hesselmark; Eva Serlachius; Luisa Lázaro; Christian Rück; Ralf Kuja-Halkola; Brian M D'Onofrio; Henrik Larsson; David Mataix-Cols Journal: JAMA Psychiatry Date: 2018-01-01 Impact factor: 21.596
Authors: Joseph Biederman; Maura DiSalvo; Ronna Fried; K Yvonne Woodworth; Itai Biederman; Stephen V Faraone Journal: J Adolesc Health Date: 2019-07-23 Impact factor: 5.012
Authors: William E Pelham; Amy R Altszuler; Brittany M Merrill; Joseph S Raiker; Fiona L Macphee; Marcela Ramos; Elizabeth M Gnagy; Andrew R Greiner; Erika K Coles; Carol M Connor; Christopher J Lonigan; Lisa Burger; Anne S Morrow; Xin Zhao; James M Swanson; James G Waxmonsky; William E Pelham Journal: J Consult Clin Psychol Date: 2022-05
Authors: George J DuPaul; Matthew J Gormley; Arthur D Anastopoulos; Lisa L Weyandt; Jeffrey Labban; Aliza Jaffe Sass; Chelsea Z Busch; Melanie K Franklin; Kaicee B Postler Journal: J Clin Child Adolesc Psychol Date: 2021-02-02
Authors: Stephen V Faraone; Tobias Banaschewski; David Coghill; Yi Zheng; Joseph Biederman; Mark A Bellgrove; Jeffrey H Newcorn; Martin Gignac; Nouf M Al Saud; Iris Manor; Luis Augusto Rohde; Li Yang; Samuele Cortese; Doron Almagor; Mark A Stein; Turki H Albatti; Haya F Aljoudi; Mohammed M J Alqahtani; Philip Asherson; Lukoye Atwoli; Sven Bölte; Jan K Buitelaar; Cleo L Crunelle; David Daley; Søren Dalsgaard; Manfred Döpfner; Stacey Espinet; Michael Fitzgerald; Barbara Franke; Manfred Gerlach; Jan Haavik; Catharina A Hartman; Cynthia M Hartung; Stephen P Hinshaw; Pieter J Hoekstra; Chris Hollis; Scott H Kollins; J J Sandra Kooij; Jonna Kuntsi; Henrik Larsson; Tingyu Li; Jing Liu; Eugene Merzon; Gregory Mattingly; Paulo Mattos; Suzanne McCarthy; Amori Yee Mikami; Brooke S G Molina; Joel T Nigg; Diane Purper-Ouakil; Olayinka O Omigbodun; Guilherme V Polanczyk; Yehuda Pollak; Alison S Poulton; Ravi Philip Rajkumar; Andrew Reding; Andreas Reif; Katya Rubia; Julia Rucklidge; Marcel Romanos; J Antoni Ramos-Quiroga; Arnt Schellekens; Anouk Scheres; Renata Schoeman; Julie B Schweitzer; Henal Shah; Mary V Solanto; Edmund Sonuga-Barke; César Soutullo; Hans-Christoph Steinhausen; James M Swanson; Anita Thapar; Gail Tripp; Geurt van de Glind; Wim van den Brink; Saskia Van der Oord; Andre Venter; Benedetto Vitiello; Susanne Walitza; Yufeng Wang Journal: Neurosci Biobehav Rev Date: 2021-02-04 Impact factor: 9.052